115 related articles for article (PubMed ID: 38097483)
1. A national study of postoperative thyroid hormone supplementation rates after thyroid lobectomy.
Hu QL; Chen L; Kuo EJ; Lee JA; Kuo JH; Wright JD; McManus CM
Surgery; 2024 Apr; 175(4):1029-1033. PubMed ID: 38097483
[TBL] [Abstract][Full Text] [Related]
2. Postoperative thyroid hormone supplementation rates following thyroid lobectomy.
Wilson M; Patel A; Goldner W; Baker J; Sayed Z; Fingeret AL
Am J Surg; 2020 Nov; 220(5):1169-1173. PubMed ID: 32684294
[TBL] [Abstract][Full Text] [Related]
3. Is thyroid hormone supplementation avoidable for patients with low-risk papillary thyroid cancer after thyroid lobectomy? A two-center observational study.
Xiao L; Wu J; Jiang L; Xu Y; Liu B
Clin Endocrinol (Oxf); 2022 Mar; 96(3):413-418. PubMed ID: 34398464
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up.
Kim SY; Kim HJ; Kim SM; Chang H; Lee YS; Chang HS; Park CS
Front Endocrinol (Lausanne); 2020; 11():520. PubMed ID: 32849303
[No Abstract] [Full Text] [Related]
5. Postoperative thyroid hormone supplementation rates following thyroid lobectomy.
Wilson M; Patel A; Goldner W; Baker J; Sayed Z; Fingeret AL
Am J Surg; 2021 Apr; 221(4):804-808. PubMed ID: 32682499
[TBL] [Abstract][Full Text] [Related]
6. Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?
Cox C; Bosley M; Southerland LB; Ahmadi S; Perkins J; Roman S; Sosa JA; Carneiro-Pla D
Surgery; 2018 Jan; 163(1):75-80. PubMed ID: 29122328
[TBL] [Abstract][Full Text] [Related]
7. Thyroidectomy Practice After Implementation of the 2015 American Thyroid Association Guidelines on Surgical Options for Patients With Well-Differentiated Thyroid Carcinoma.
Hirshoren N; Kaganov K; Weinberger JM; Glaser B; Uziely B; Mizrahi I; Eliashar R; Mazeh H
JAMA Otolaryngol Head Neck Surg; 2018 May; 144(5):427-432. PubMed ID: 29596551
[TBL] [Abstract][Full Text] [Related]
8. Endocrine surgeons are performing more thyroid lobectomies for low-risk differentiated thyroid cancer since the 2015 ATA guidelines.
Conroy PC; Wilhelm A; Calthorpe L; Ullmann TM; Davis S; Huang CY; Shen WT; Gosnell J; Duh QY; Roman S; Sosa JA
Surgery; 2022 Nov; 172(5):1392-1400. PubMed ID: 36002375
[TBL] [Abstract][Full Text] [Related]
9. Surveillance and intervention after thyroid lobectomy.
Spanheimer PM; Sugg SL; Lal G; Howe JR; Weigel RJ
Ann Surg Oncol; 2011 Jun; 18(6):1729-33. PubMed ID: 21246403
[TBL] [Abstract][Full Text] [Related]
10. Analysis of an institutional protocol for thyroid lobectomy: Utility of routine intraoperative frozen section and expedited (overnight) pathology.
Berg RW; Yen TW; Evans DB; Hunt B; Quiroz FA; Wilson SD; Wang TS
Surgery; 2016 Feb; 159(2):512-7. PubMed ID: 26361834
[TBL] [Abstract][Full Text] [Related]
11. Thyroid hormone replacement following lobectomy: Long-term institutional analysis 15 years after surgery.
Barranco H; Fazendin J; Lindeman B; Chen H; Ramonell KM
Surgery; 2023 Jan; 173(1):189-192. PubMed ID: 36202649
[TBL] [Abstract][Full Text] [Related]
12. 2015 American Thyroid Association guidelines and thyroid-stimulating hormone suppression after thyroid lobectomy.
Reed R; Strumpf A; Martz TG; Kavanagh KJ; Fedder KL; Jameson MJ; Shonka DC
Head Neck; 2021 Feb; 43(2):639-644. PubMed ID: 33124116
[TBL] [Abstract][Full Text] [Related]
13. Thyroid lobectomy for indeterminate FNA: not without consequences.
Balentine CJ; Domingo RP; Patel R; Laucirica R; Suliburk JW
J Surg Res; 2013 Sep; 184(1):189-92. PubMed ID: 23777982
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, treatment, and outcome of follicular thyroid carcinoma.
Emerick GT; Duh QY; Siperstein AE; Burrow GN; Clark OH
Cancer; 1993 Dec; 72(11):3287-95. PubMed ID: 8080485
[TBL] [Abstract][Full Text] [Related]
15. Thyroid hormone replacement after thyroid lobectomy.
Stoll SJ; Pitt SC; Liu J; Schaefer S; Sippel RS; Chen H
Surgery; 2009 Oct; 146(4):554-8; discussion 558-60. PubMed ID: 19789012
[TBL] [Abstract][Full Text] [Related]
16. The Identification of Intraoperative Risk Factors Can Reduce, but Not Exclude, the Need for Completion Thyroidectomy in Low-Risk Papillary Thyroid Cancer Patients.
Craig SJ; Bysice AM; Nakoneshny SC; Pasieka JL; Chandarana SP
Thyroid; 2020 Feb; 30(2):222-228. PubMed ID: 31813323
[No Abstract] [Full Text] [Related]
17. Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy.
DiMarco AN; Wong MS; Jayasekara J; Cole-Clark D; Aniss A; Glover AR; Delbridge LW; Sywak MS; Sidhu SB
BJS Open; 2019 Jun; 3(3):299-304. PubMed ID: 31183445
[TBL] [Abstract][Full Text] [Related]
18. Changes in total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer during the past 15 years.
James BC; Timsina L; Graham R; Angelos P; Haggstrom DA
Surgery; 2019 Jul; 166(1):41-47. PubMed ID: 30904172
[TBL] [Abstract][Full Text] [Related]
19. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma.
Untch BR; Palmer FL; Ganly I; Patel SG; Michael Tuttle R; Shah JP; Shaha AA
Ann Surg Oncol; 2014 Apr; 21(4):1374-8. PubMed ID: 24366419
[TBL] [Abstract][Full Text] [Related]
20. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
Na YM; Cho JS; Park MH
Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
